• Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 679 shares on Aug. 10 at USD 20.
• Sale followed an option exercise for 679 shares at USD 8.04.
• Mittie ended the day with 51,776 shares of common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001918845-26-000026), on August 12, 2026, and is solely responsible for the information contained therein.